Top Markets
Coin of the day
Immunovia AB Immunovia AB

Immunovia AB

IMMNOV
Rank in Stocks #34136
Immunovia AB (publ), a diagnostic company, develops blood diagnostic for... Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Share Price
$0.018005
Last synced: 2026-08-14
Market Cap
$6.17M
Change (1 day)
-1.71%
Change (1 year)
-60.12%
Country
SE
Trade Immunovia AB (IMMNOV)

Category

P/E ratio for Immunovia AB (IMMNOV)
P/E ratio as of 2026 TTM: 0
According to Immunovia AB latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Immunovia AB from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
31.59 -
US
35.83 -
US
- -
CN
-227.89 -
US
38.69 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.